@article{khanna:hal-03355294,
TITLE = {SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: How to incorporate two Food and Drug Administration-approved therapies in clinical practice},
AUTHOR = {Khanna, Dinesh and Lescoat, Alain and Roofeh, David and Bernstein, Elana J and Kazerooni, Ella A and Roth, Michael D and Martinez, Fernando and Flaherty, Kevin R and Denton, Christopher P},
URL = {https://hal.science/hal-03355294},
JOURNAL = {Arthritis and Rheumatology (hoboken, N.j.)},
VOLUME = {74},
NUMBER = {1},
PAGES = {13-27},
YEAR = {2022},
MONTH = Jan, DOI = {10.1002/art.41933},
KEYWORDS = {lung fibrosis ; mycophenolate mofetil ; nintedanib ; stem cell transplant ; tocilizumab ; Systemic sclerosis ; cyclophosphamide ; interstitial lung disease},
PDF = {https://hal.science/hal-03355294/file/Khanna%20et%20al-2021-SYSTEMIC%20SCLEROSIS-ASSOCIATED%20INTERSTITIAL%20LUNG%20DISEASE.pdf},
HAL_ID = {hal-03355294},
HAL_VERSION = {v1},
}